Advanced Medical Solutions Grp PLC Pre-Close Trading Update (8876R)
December 15 2016 - 2:00AM
UK Regulatory
TIDMAMS
RNS Number : 8876R
Advanced Medical Solutions Grp PLC
15 December 2016
15 December 2016
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Pre-Close Trading Update
Winsford, UK, 15 December: Advanced Medical Solutions Group plc
(AIM: AMS.L), the surgical and advanced wound care specialist
company, today announces an update on trading for the year ending
31 December 2016.
The Group continues to make good progress and the Board expects
profitability to be in line with current market expectations,
whilst revenue is expected to be ahead of market expectations,
aided by the weakness in sterling against the US dollar and the
euro.
The immediate benefit of the weakness of sterling to profit is
delayed as the Group's policy is to hedge significant transactional
exposure by using forward contracts and options and aims to have at
least 70% of its estimated transactional exposure for the next
twelve months hedged.
Chris Meredith, Chief Executive Officer of AMS, said: "The Group
continues to deliver strong organic growth from its existing
product portfolio. This growth is further supported by our Research
and Development activities that provide product innovation allowing
us to maintain our leadership position in our chosen market
segments. AMS is well positioned to continue on its growth
trajectory."
The Group expects to publish its Preliminary Results for the
year to 31 December 2016 in March 2017.
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group Tel: +44 (0)
plc 1606 545508
Chris Meredith, Chief Executive
Officer
Mary Tavener, Group Finance Director
Consilium Strategic Communications Tel: +44 (0)
20 3709 5700
Mary-Jane Elliott / Jonathan
Birt / Matthew Neal / Hendrik
Thys
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0)
20 7597 5970
Daniel Adams / Patrick Robb
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical, wound care and wound closure markets, focused on quality
outcomes for patients and value for payors. AMS has a wide range of
products that include silver alginates, alginates, foams, tissue
adhesives, sutures and haemostats, which it markets under its
brands; ActivHeal(R), LiquiBand(R) and RESORBA(R) as well as
supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in
the Netherlands, two in Germany and one in the Czech Republic, are
sold in more than 75 countries via a network of multinational or
regional partners and distributors, as well as via AMS's own direct
sales forces in the UK, Germany, the Czech Republic and Russia.
Established in 1991, the Company has 530 employees. For more
information please see www.admedsol.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFVDFFLSLIR
(END) Dow Jones Newswires
December 15, 2016 02:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024